Evidence map›Paper›PMID 31575562›Full record

ArticleCancer discovery2019

Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?

Jose M Pacheco, Lauren Averett Byers

Registry-linked trialAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05092412 (A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05092412 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin for Patients With Extensive-stage Small Cell Lung Cancer

TypeinterventionalSponsorYou LuRan2022 to 2027Enrolled30ConditionsLung Cancer, Extensive-stage Small-cell Lung Cancer, DurvalumabArmsLow-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jose M PachecoDepartment of Internal Medicine, Division of Medical Oncology, University of Colorado Anschutz Cancer Center, Aurora, Colorado. jose.m.pacheco@cuanschutz.edu.
Lauren Averett ByersDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-0780-2677
The University of Texas MD Anderson Cancer Center · USUniversity of Colorado Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective options are limited for patients with small-cell lung cancer who develop progressive disease during or after etoposide plus platinum-based therapy. In this issue of

Indexed as

Lung NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAnimalsBiomarkersCell Line, TumorHeterograftsHumansNeoplasm Recurrence, LocalPhthalazinesPiperazinesTemozolomideXenograft Model Antitumor AssaysBiomarkersolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsTemozolomide

Identifiers

PMID31575562
OpenAlexW2977621919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.